重症患者的皮质类固醇:一个叙述性审查
Bradley J Haan1, Samantha N Blackmon2, Alex M Cobb3
1Department of Pharmacy, Ascension Genesys Hospital, Grand Blanc, Michigan, USA.
Pharmacotherapy
|June 14, 2024
概括
皮质类固醇在重症监护中提供了好处,但也带有重大风险. 谨慎的患者管理至关重要,以平衡ARDS和败血性休克等疾病的疗效和不良影响.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 临床研究是临床研究.
背景情况:
- 皮质类固醇在医学中被广泛使用,已知有好处和危害.
- 危急病患者面临来自皮质类固醇并发症和并发症的风险增加.
- 确定的适应症包括ARDS,感染性休克和COPD等.
研究的目的:
- 提供关于在重症监护中使用皮质类固醇的全面审查.
- 详细介绍各种危急疾病状态的益处和危害.
- 为指导皮质类固醇的适当治疗利用.
主要方法:
- 现有文献的叙述性审查.
- 对皮质类固醇的益处和不良影响的分析.
- 检查在特定重症监护病情中的利用情况.
主要成果:
- 皮质类固醇可以改善结果,减少住院时间,降低死亡率.
- 副作用包括高血糖症,免疫抑制和胃肠道出血.
- 与医疗保健成本的增加有关.
结论:
- 在重症监护中的皮质类固醇治疗需要仔细评估风险和益处.
- 管理策略必须减轻不利影响.
- 本综述巩固了当前关于在严重疾病中使用皮质类固醇的知识.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
195
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
195
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
236
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
236
Drugs Used in Lower Respiratory Disorders: Overview
412
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
412
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Acute Respiratory Failure-V
132
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
132


